You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
來凱醫藥(02105.HK)發表LAE102治療肥胖症等研究數據
阿思達克 06-23 10:05
來凱醫藥(02105.HK)公布,近日於美國糖尿病協會(ADA)第85屆科學年會上,發布旗下產品LAE102用於治療肥胖症的一期單劑量遞增(SAD)研究結果,以及LAE102、LAE103及LAE123作為增肌減脂療法的臨床前研究結果。公司指,在臨床前模型中,LAE102已顯示出增加肌肉並減少脂肪的效果,而LAE102與GLP-1受體激動劑聯用可進一步減少脂肪,並顯著降低GLP-1受體激動劑導致的肌肉流失,使LAE102成為一種高質量體重控制候選藥物。 來凱醫藥指,LAE103和LAE123已推進至IND支持性研究階段,目前正積極推動相關候選藥物進入臨床研究,作為治療肌肉疾病及其他適應症的新型療法。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account